𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Switching to quetiapine in patients with acute mania who were intolerant to risperidone

✍ Scribed by Chi-Un Pae; Kyong-Uk Lee; Jung-Jin Kim; Chang-Uk Lee; Won-Myong Bahk; Soo-Jung Lee; Chul Lee; In-Ho Paik

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
67 KB
Volume
19
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study evaluated the overall efficacy and tolerability of quetiapine in the treatment of inpatients with acute mania who are intolerant to risperidone in combination with a mood stabilizer. Eighteen patients completed this 3‐week trial. The efficacy and tolerability was assessed upon admission, at baseline, and 1 and 3 weeks later. The Young mania rating scale (YMRS) and clinical global impression‐severity (CGI‐s) scores from the baseline to the endpoint, decreased by 39.8% and 40.0%, respectively. Fifteen (78.9%) and 18 (94.7%) patients exhibited at least a 50% improvement in the YMRS and CGI‐s scores by the end of the trial. Measurements taken through the Barnes akathisia rating scale (BARS), the Simpson‐Angus rating scale (SARS) and the drug attitude inventory shortened version‐10 (DAI‐10) also showed significant improvement.

This study suggests that quetiapine may hold promise as an alternative regimen that does not worsen the psychopathology, particularly for those vulnerable to the side effects of drugs, including atypical agents such as risperidone, in naturalistic treatment settings. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Efficacy and tolerability of quetiapine
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone
✍ Ilkka Larmo; André de Nayer; Elmar Windhager; Irmansyah; Bernhard Lindenbauer; H 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract A __post hoc__ analysis of the SPECTRUM trial was carried out to evaluate whether the improvements in efficacy and tolerability gained on switching to quetiapine occurred consistently for patients previously treated with either: haloperidol (__n__ = 43); olanzapine (__n__ = 66); or risp

Effectiveness of antipsychotic polypharm
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
✍ Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and ris

Effects of switching to long-acting inje
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
✍ Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Seung-Hyun Lee; Yo-Han Lee; Su-Jin Yang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral